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A live attenuated bovine parainfluenza virus type 3 (PIV3), harboring the fusion (F) and hemagglutinin-
neuraminidase (HN) genes of human PIV3, was used as a virus vector to express surface glycoproteins derived
from two human pathogens, human metapneumovirus (hMPV) and respiratory syncytial virus (RSV). RSV and
hMPV are both paramyxoviruses that cause respiratory disease in young children, the elderly, and immuno-
compromised individuals. RSV has been known for decades to cause acute lower respiratory tract infections in
young children, which often result in hospitalization, while hMPV has only been recently identified as a novel
human respiratory pathogen. In this study, the ability of bovine/human PIV3 to express three different foreign
transmembrane surface glycoproteins and to induce a protective immune response was evaluated. The RNA-
dependent RNA polymerase of paramyxoviruses binds to a single site at the 3 end of the viral RNA genome
to initiate transcription of viral genes. The genome position of the viral gene determines its level of gene
expression. The promoter-proximal gene is transcribed with the highest frequency, and each downstream gene
is transcribed less often due to attenuation of transcription at each gene junction. This feature of paramyxo-
viruses was exploited using the PIV3 vector by inserting the foreign viral genes at the 3 terminus, at position
1 or 2, of the viral RNA genome. These locations were expected to yield high levels of foreign viral protein
expression stimulating a protective immune response. The immunogenicity and protection results obtained
with a hamster model showed that bovine/human PIV3 can be employed to generate bivalent PIV3/RSV or
PIV3/hMPV vaccine candidates that will be further evaluated for safety and efficacy in primates.
Despite control of many infectious diseases in the industri-
alized world, acute viral respiratory tract infections remain a
leading cause of illness and reason for hospitalization. Two
paramyxoviruses, respiratory syncytial virus (RSV) and human
parainfluenza virus type 3 (hPIV3), are the causative agents of
acute respiratory diseases of infancy and early childhood, re-
sulting in 20 to 25% of pneumonia and 45 to 50% of bronchi-
olitis in hospitalized children (8). In addition, a recently iden-
tified human metapneumovirus (hMPV) appears to be
associated with lower respiratory tract infections in children
(25). Preliminary epidemiological reports have estimated an
hMPV disease incidence rate of 7 to 10% in young children (5,
11, 16, 18, 25). The symptoms of hMPV infections are similar
to those caused by RSV and hPIV3, and hospitalizations of
young children with acute lower respiratory tract infections are
necessary in some cases (17). Recently, Greensill et al. re-
ported the detection of hMPV in bronchoalveolar lavage fluids
from 21 of 30 infants (70%) ventilated for RSV bronchiolitis
(7).
RSV remains one of the most common respiratory patho-
gens afflicting infants, the elderly, and immunocompromised
individuals. Hospitalization and immunoglobulin treatment
are often necessary to alleviate serious RSV infections. For
decades, approaches to generate an RSV vaccine employing
virus subunits or inactivated virus vaccines have failed either
due to lack of immunogenicity or the potential for causing
enhanced pulmonary disease upon reinfection with naturally
occurring wild-type RSV. The advent of reverse genetics for
negative-strand RNA viruses resulted in a plethora of geneti-
cally designed RSV vaccine candidates that harbor mutations
in essential RSV genes or deletions of nonessential RSV genes
in an effort to attenuate virus replication without compromis-
ing immunogenicity (3). The results from these studies clearly
demonstrated that an RSV vaccine candidate must be properly
fine tuned to balance immunogenicity and attenuation for ad-
ministration to 1- to 2-month-old infants. If the RSV candidate
vaccine is insufficiently attenuated, the children will show signs
of disease. If the vaccine virus does not replicate enough, the
level of immunogenicity elicited in the immunized children will
be low and ineffective (4). Two subgroups of RSV (A and B)
circulate at any given time. The F proteins of the two RSV
subgroups are highly conserved (98% amino acid identity),
unlike the RSV attachment glycoproteins (G), which display
only 53% identity at the amino acid level.
hPIV3 is the causative agent of croup, an acute lower respi-
ratory disease most often observed in young children (6, 8, 29).
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Two live attenuated hPIV3 vaccine candidates have been eval-
uated so far in human clinical trials. A live attenuated bovine
PIV3, a Jennerian-type vaccine, was administered to children
between 2 and 6 months of age in human clinical trials and was
shown to be safe and immunogenic (12, 14). A cold-passaged
hPIV3 strain that displayed a temperature-sensitive phenotype
(cpts-hPIV3) was also shown to be immunogenic in human
clinical trials (13, 23).
hMPV causes clinical symptoms similar to those of RSV,
ranging from mild respiratory problems to severe cough, bron-
chiolitis, and pneumonia (2, 25). Two subgroups of hMPV
(clades A and B) were identified based on sequence compar-
ison of the F and G genes derived from a number of different
clinical isolates. The F genes of clades A and B are highly
conserved and display 95% identity at the amino acid level.
In contrast, the hMPV G proteins are variable and show only
a 35% amino acid identity (R. A. M. Fouchier, personal com-
munication). On the basis of electron microscopy and compar-
ison of gene constellations and sequences, hMPV has been
assigned to the Metapneumovirus genus of the Paramyxoviridae
family. hMPV displays a unique gene organization (3 N-P-M-
F-M2-SH-G-L 5) that is similar to but unlike that of either
PIV3 or RSV (24, 25). Efforts to prepare neutralizing hMPV
monoclonal and polyclonal antisera and to generate live atten-
uated hMPV vaccines have been initiated by a number of
research laboratories in the United States, Canada, Europe,
and Australia.
Food and Drug Administration-approved vaccines for RSV,
hPIV3, or hMPV are not currently available. However, a de-
sirable and marketable vaccine product would likely contain
virus vaccines effective against all three respiratory pathogens,
RSV, hPIV3, and hMPV, since all of these viruses are respon-
sible for extensive morbidity and mortality in the same popu-
lation, young children.
In this study, we investigated the suitability of a chimeric
bovine/human PIV3 (b/h PIV3), itself a vaccine candidate for
hPIV3, to serve as a live, attenuated virus vaccine vector to
express the RSV F, RSV G, or hMPV F proteins. The b/h
PIV3 virus vector harbors the F and HN genes of hPIV3 (9).
Bivalent vaccine candidates were generated that expressed
RSV or hMPV surface glycoproteins. Antibodies produced in
response to expression of the surface glycoproteins of RSV,
the fusion protein (F) and G, or the F protein of hMPV by b/h
PIV3 are expected to result in cross-neutralizing and cross-
protection against infection by all strains of RSV or hMPV,
respectively, because the RSV F genes are highly conserved
between subgroups A and B of RSV, and the hMPV F genes of
clades A and B show a high degree of conservation. The for-
eign antigens were inserted in the two 3-most proximal posi-
tions of the b/h PIV3 RNA genome. Position 1 is located
between the native bPIV3 leader and the bPIV3 N gene, and
position 2 is juxtaposed between the bPIV3 N and P genes.
Since the paramyxovirus RNA-dependent RNA polymerase
enters at a single site at the very 3 end of the genomic RNA
to initiate sequential transcription of viral genes, a transcrip-
tion gradient was generated in which genes located proximal to
the 3 terminus of the viral RNA are transcribed at a higher
frequency, yielding higher levels of protein expression (15). In
order to achieve maximum levels of protein expression, the
positions at the 3 end that were selected for gene insertion
should not compromise the replication efficiency of the result-
ing chimeric viruses.
Recombinant b/h PIV3 expressing RSV or hMPV surface
glycoproteins from position 1 or 2 in the PIV3 genome was
analyzed for levels of antigen expression, replication in tissue
culture, replication in a small animal model, and the ability to
elicit an immune response. All of these viruses expressed the
RSV or hMPV proteins efficiently in both of the positions used
for gene insertion into the PIV3 genome. This study further
evaluated whether structurally similar antigens would result in
chimeric viruses with similar phenotypes and whether the for-
eign glycoproteins derived from hMPV or RSV were function-
ally incorporated into the b/hPIV3 envelope. The RSV F, RSV
G, or hMPV F gene products display structural features that
identify them as integral membrane proteins. These proteins
possess functionally similar domains such as transmembrane
regions and signal peptides that enable them to be incorpo-
rated into PIV3 envelope and serve as targets for the host
immune response. Animals immunized with the chimeric b/h
PIV3/RSV or b/h PIV3/hMPV were protected in challenge
studies from both RSV or hMPV and PIV3 and produced
neutralizing RSV or hMPV antibodies and PIV3 HAI antibod-
ies. The most promising b/h PIV3/RSV and b/h PIV3/hMPV F
vaccine candidates will be evaluated for safety and efficacy in
primates and humans.
MATERIALS AND METHODS
Cells and viruses. The RSV A2 strain, b/h PIV3, the hMPV/NL/1/00 strain, b/h
PIV3/RSV, and b/h PIV3/hMPV viruses were grown in Vero cells in Opti-MEM
(minimal essential medium) (Gibco/BRL) in the presence of gentamicin. Mod-
ified vaccinia virus Ankara (MVA-T7) or fowlpox-T7 virus (FP-T7), which ex-
pressed the phage T7 RNA polymerase, was grown in chicken embryonic kidney
cells (SPAFAS). Vero, HeLa, and HEp-2 cells were maintained in MEM (JRH
Biosciences) supplemented with 10% fetal bovine serum (FBS), 2 mM L-glu-
tamine, nonessential amino acids, and antibiotics.
Construction of b/h PIV3/RSV and b/h PIV3/hMPV full-length cDNAs. To
insert foreign genes into the b/h PIV3 cDNA, AvrII restriction enzyme sites were
introduced in the b/h PIV3 cDNA plasmid (9, 10) by site-directed mutagenesis
with the QuikChange kit (Stratagene). One AvrII site was introduced at nucle-
otide (nt) 104 in the b/h PIV3 genome, altering 4 nt with the oligonucleotide
5GAAATCCTAAGACCCTAGGCATGTTGAGTC3 and its complement.
This restriction enzyme site was used to insert the RSV genes in the first (3
proximal) position in the viral genome. Another AvrII site was introduced in the
N-P intergenic region at nt 1774, changing 2 nt by using the oligonucleotide
5CCACAACTCAATCAACCTAGGATTCATGGAAGACAATG3 and its
complement. This restriction site was used (designated F1 or G1) to insert the
RSV genes in the second position between the N and P genes of b/h PIV3
(designated F2 or G2) (Fig. 1). Viruses harboring the AvrII sites at nt 104 and
1774 were recovered from full-length b/h PIV3 cDNAs.
Construction of the RSV G cassette. A DNA fragment was generated that
contained the bPIV3 N-P intergenic region as well as the 3-end sequences of the
RSV G gene, using the b/h PIV3 cDNA as PCR template. This fragment was
generated by PCR with the oligonucleotides 5CCCAACACACCACGCCAGT
AGTCACAAAGAGATGACCACTATCAC3 and 5CCCAAGCTTCCTAGG
TGAATCTTTGGTTGATTGAGTTGTGG3. This fragment was then used in
overlapping PCR to add the bPIV3 N-P intergenic region to the RSV G gene.
The resulting PCR fragment containing the RSV G open reading frame (ORF)
with the bPIV3 N-P intergenic region flanked by AvrII restriction enzyme sites
was cloned into pGEM3.
Construction of the hMPV F cassette. A plasmid (pRF515) carrying the hMPV
F gene (strain NL/1/00) was obtained from R. Fouchier. The bPIV3 N-P inter-
genic region was added at the 3 end of the hMPV F gene by using overlapping
PCRs, and the hMPV F gene cassette with flanking AvrII sites was generated in
the same manner as described for the RSV G cassette.
Construction of the RSV F cassette. The RSV F gene fragment was isolated by
PCR from a full-length bPIV3/RSV FG cDNA plasmid by using oligonucleo-
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tides that added AvrII sites at the 5 and 3 ends of the RSV F gene. The RSV
F gene was introduced into the 1-5 bPIV3 plasmid, containing the first 5,200 nt
of the bPIV3 genome and the AvrII site at nt 1774, which was linearized with
AvrII. The bPIV3 N-P intergenic region was isolated by PCR. The oligonucleo-
tide 5GACGCGTCGACCACAAAGAGATGACCACTATCACC3 and an oli-
gonucleotide annealing in the bPIV3 F ORF were used to generate a PCR
fragment containing the bPIV3 N-P intergenic region, AvrII site, and bPIV3
sequences up to nt 5200. The PCR fragment was added to the 1-5 bPIV3 plasmid
harboring the RSV F gene at position 2 using SalI and NheI sites.
The RSV G, RSV F, and hMPV F gene cassettes were sequenced to confirm
the presence of an intact ORF, the predicted amino acid sequences, and to verify
the rule of six. The RSV G, RSV F, and hMPV F transcriptional units were
inserted into the first or second position by using the AvrII restriction enzyme
sites into a subclone of 1-5 bPIV3. After confirming the proper orientation by
restriction enzyme mapping, the plasmids with the RSV genes in the first position
were digested with SphI and BssHII and 4-kb (1-5 RSV G1) or 4.8-kb (1-5 RSV
F1 or 1-5 hMPV F1) DNA fragments were isolated. The rest of the b/h PIV3
genome was ligated as a 15.1-kb SphI-BssHII DNA fragment, yielding full-length
cDNAs. The bPIV3 subclones harboring the RSV genes in the second position
were cut with SphI and NheI, and 5.8-kb (bPIV3/RSV G2) and 6.5-kb (bPIV3/
RSV F2 or bPIV3/hMPV F2) DNA fragments were isolated. The rest of the b/h
PIV3 genome was ligated as an NheI-SphI DNA fragment of 14 kb in size to
generate full-length cDNA plasmids.
Recombinant virus recovery by reverse genetics. Infectious virus was recov-
ered by reverse genetics in HeLa or HEp-2 cells by transfection methods de-
scribed previously (9). Briefly, HEp-2 or Vero cells at 80 to 90% confluency in
six-well tissue culture dishes were infected with FP-T7 or MVA-T7 at a multi-
plicity of infection (MOI) of 0.1 to 0.3 or 1 to 5, respectively. Following infection
with FP-T7 or MVA-T7, cells were washed once with phosphate-buffered saline
(PBS) and transfected with the following amounts of plasmid DNA: 2.0 g of
full-length b/h PIV3 cDNA, 0.4 g of pCITE/N, 0.4 g of pCITE/P, and 0.2 g
of pCITE/L. Transfections were performed in the presence of Lipofectamine
2000 (Invitrogen) according to the manufacturer’s instructions. The transfection
reaction mixtures were incubated at 33°C for 5 to 12 h, after which the medium
containing Lipofectamine 2000 was replaced with 2 ml of fresh Opti-MEM
containing gentamicin. The transfected cells were incubated further at 33°C for
2 days. Cells were stabilized with 1 SPG (10 SPG is 2.18 M sucrose, 0.038 M
KH2PO4, 0.072 M K2HPO4, and 0.054 M L-glutamate) and lysed with one
freeze-thaw cycle at 80°C. The crude cell lysate was used to infect a new Vero
cell monolayer in order to amplify rescued viruses. The chimeric viruses were
cloned by limiting dilutions in Vero cells and stocks of 106 to 108 PFU/ml were
generated. The RSV or hMPV genes of the chimeric viruses were isolated by
reverse transcription-PCR (RT-PCR), and the sequences were confirmed. Ex-
pression of the RSV proteins was confirmed by immunostaining infected Vero
cell monolayers with RSV goat polyclonal antiserum (Biogenesis). Expression of
the hMPV F protein was confirmed by immunostaining with polyclonal hMPV
guinea pig antiserum (R. Fouchier).
Growth curves of b/h PIV3/RSV or b/h PIV3/hMPV chimeric viruses. Vero
cells were grown to 90% confluence and infected at an MOI of 0.01 or 0.1 with
b/h PIV3, b/h PIV3/RSV F1, b/h PIV3/RSV G1, b/h PIV3/RSV F2, b/h PIV3/
RSV G2, b/h PIV3/hMPV F1, or b/h PIV3/hMPV F2. The infected monolayers
were incubated at 37°C. At 0, 24, 48, 72, 96, and 120 h postinfection (hpi), cells
and media were harvested and stored at 70°C. Virus titers for each time point
harvest were determined by 50% tissue culture infective dose (TCID50) or
plaque assays in Vero cells. TCID50 assays were inspected visually for cytopathic
effect (CPE) following incubation at 37°C for 6 days, while plaque assays were
immunostained with RSV or hMPV polyclonal antisera for quantification after 5
days of incubation at 35°C.
Western blotting of RSV proteins expressed by b/h PIV3/RSV chimeric vi-
ruses. Chimeric viruses were used to infect (70 to 80%) subconfluent Vero cells
at an MOI of 0.1. Forty-eight hours postinfection, the medium overlay was
removed, and infected monolayers were washed once with 1 ml of PBS. The cells
were subsequently lysed in 400 l of Laemmli buffer (Bio-Rad) containing 5%
-mercaptoethanol (Sigma). Fifteen microliters of each sample was separated on
12% Tris-HCl Ready Gel (Bio-Rad) and transferred to nylon membranes by
using a semidry transfer cell (Bio-Rad). Nylon membranes were rinsed in PBS
(pH 7.6) containing 0.5% (vol/vol) Tween 20 (Sigma) (PBST) and blocked with
PBST containing 5% (wt/vol) dry milk (PBST-M) for 20 to 30 min at room
temperature. Membranes were incubated with either a mixture of RSV F mono-
clonal antibodies (MAbs WHO 1269, 1200, 1153, 1112, 1243, and 1107) (1) at a
1:1,000 dilution in PBST-M or RSV G 10181 polyclonal antibody (Orbigen) at a
1:2,000 dilution in PBST-M for 1 h at room temperature. Following four washes
with PBST, the membranes were incubated with a secondary horseradish per-
oxidase-conjugated goat anti-mouse antibody (Dako) at a 1:2,000 dilution in
PBST-M for 1 h at room temperature. Membranes were washed four times with
PBST, developed with a chemiluminescence substrate (Amersham Pharmacia),
and exposed to Biomax Light Film (Kodak) for visualization of protein bands.
Immunoprecipitation of hMPV F proteins expressed by b/h PIV3/hMPV. For
immunoprecipitation of the hMPV F protein expressed by b/h PIV3/hMPV,
Vero cells were infected with b/h PIV3 or b/h PIV3/hMPV F1 or F2 at an MOI
of 0.05. Twenty-four hours postinfection, the cells were incubated for 30 min in
Dulbecco’s modified Eagle’s medium (DME) lacking cysteine and methionine
(ICN). The medium was removed, and 0.5 ml of DME lacking cysteine and
methionine containing 100 Ci of [35S]Pro-Mix (Amersham) was added to the
cells. The infected cells were incubated in the presence of 35S isotopes for 5 h at
37°C. The medium was removed, and the infected cells were lysed in radioim-
munoprecipitation assay (RIPA) buffer containing 0.15 M NaCl. The cell lysate
was incubated with guinea pig or human polyclonal antisera against hMPV and
FIG. 1. Schematic representation of the b/h PIV3 RNA genome, which serves as a vector backbone for insertion of RSV or hMPV surface
glycoprotein genes. The RSV F, RSV G, and hMPV F gene insertions at position 1 or 2 of the PIV3 genome are indicated by gray boxes. The
foreign genes were inserted at position 1 by using an AvrII restriction enzyme site introduced at nt 104 in the PIV3 genome or at position 2 at an
AvrII site at nt 1774. The inserted transcriptional units contain the bPIV3 N-P intergenic region with the gene stop and start sequences utilized
for transcription of the gene downstream of the inserted cassette.
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bound to recombinant protein G agarose (Invitrogen) overnight at 4°C. The
agarose beads were pelleted and washed once with 0.3 M NaCl RIPA buffer and
twice with 0.15 M NaCl RIPA buffer. After a final wash with a buffer containing
0.05 M NaCl, 2.5 mM EDTA, and 0.05 M Tris-HCl (pH 7.5), the samples were
fractionated on a 10% protein gel. The gel was dried and exposed to MR film
(Kodak).
Genetic stability studies of b/h PIV3/RSV and b/h PIV3/hMPV. Subconfluent
Vero cells in T25 flasks were infected with b/h PIV3/RSV or b/h PIV3/hMPV at
an MOI of 0.1 and incubated for 4 days at 33°C or until CPE was visible. At the
end of the incubation period, the infected cells and media were harvested and
frozen and thawed two times, and the resulting cell lysate was used to infect a
new T25 flask of Vero cells. This cycle was repeated 10 times. All cell lysates from
P1 to P10 (P signifies passage number) were analyzed by plaque assay and
immunostaining for expression of RSV or hMPV proteins and virus titers. The
RSV F, RSV G, and hMPV F gene cassettes were isolated by RT-PCR from P10
lysates and sequenced to identify possible nucleotide alterations.
Replication of b/h PIV3/RSV and b/h PIV3/hMPV chimeric viruses in Syrian
Golden hamsters. Five-week-old Syrian Golden hamsters (six animals per group)
were infected intranasally with 106 PFU of b/h PIV3, b/h PIV3/RSV, RSV A2,
b/h PIV3/hMPV, hMPV/NL/1/00, or placebo medium in a 100-l volume. The
different groups were maintained separately in microisolator cages. Four days
postinfection, the nasal turbinates and lungs of the animals were harvested,
homogenized, and stored at70°C. The titers of virus present in the tissues were
determined by TCID50 assays in Vero cells. For the challenge studies, the
animals were inoculated on day 28 intranasally with 106 PFU of hPIV3, RSV A2,
or hMPV/NL/1/00 per ml. Four days postchallenge, the nasal turbinates and
lungs of the animals were isolated and assayed for challenge virus replication by
plaque assays on Vero cells. Plaques were visualized for quantitation by immu-
nostaining.
Neutralization assay. Neutralization assays were performed for b/h PIV3, b/h
PIV3/RSV chimeric viruses, or RSV on Vero cells. Serial twofold dilutions of
RSV polyclonal antiserum (Biogenesis, Poole, England), RSV F 1200 MAb
obtained from Judy Beeler and the WHO Reagent Bank (1), and hPIV3 F
(C191/9) and HN (68/2) MAbs (26, 28), were incubated with approximately 100
PFU of either b/h PIV3, b/h PIV3/RSV chimeric viruses or RSV in 0.5 ml of
Opti-MEM at room temperature for 60 min. Following the incubation, virus-
serum mixtures were transferred to Vero cell monolayers, incubated at 35°C for
1 h, overlaid with 1% methylcellulose in EMEM/L-15 medium (JRH Bio-
sciences; Lenexa, Kans.) containing 2% FBS and 1% antibiotics, and incubated
at 35°C. Six days postinoculation, the infected cell monolayers were immuno-
stained. Neutralization titers were expressed as the reciprocal of the highest
serum dilution that caused a 50% inhibition of virus titer.
Neutralization assays were also carried out for serum obtained on day 28
postinfection from hamsters immunized with b/h PIV3, b/h PIV3/RSV, or b/h
PIV3/hMPV chimeric viruses, RSV A2, or hMPV. The hamster sera were two-
fold serially diluted and incubated with 100 PFU of RSV A2 or hMPV for 1 h.
The virus-serum mixtures were transferred to Vero cell monolayers and overlaid
with methylcellulose. After 5 or 10 days of incubation at 35°C, the monolayers
were immunostained with RSV or hMPV polyclonal antiserum, respectively, for
quantitation.
HAI assay. Hemagglutination-inhibition (HAI) assays were performed by in-
cubating serial twofold dilutions of day 28 hamster sera at 25°C for 30 min with
hPIV3 in V-bottom 96-well plates. Following the addition of guinea pig eryth-
rocytes, the incubation was continued for an additional 90 min, and the presence
or absence of hemagglutination in each well was recorded. Titers were expressed
as the mean reciprocal log2 of the highest serum dilution that inhibited hemag-
glutination.
RESULTS
Recovery of chimeric PIV3 harboring the RSV F, RSV G, or
hMPV F gene in genome position 1 or 2. bPIV3 had been
shown previously to be attenuated for replication in rhesus
monkeys and safe and immunogenic in children (12, 27). The
genetic determinants specifying bPIV3 attenuation in rhesus
monkeys were shown to be located in the N, P, and L genes
(22). Based on these data, it is expected that the chimeric b/h
PIV3, harboring the hPIV3 F and HN genes, will still be
attenuated in humans, and development as a vaccine vector is
warranted. An additional degree of attenuation should result
from inserting foreign antigens such as RSV or hMPV genes
into the b/h PIV3 genome.
The surface glycoproteins of RSV are known to be respon-
sible for eliciting neutralizing antibodies. It is expected that the
highly conserved RSV F protein alone will elicit protective
immunity against both subgroup A and B RSV strains. Simi-
larly, the hMPV F protein alone should provide protection
against all clades of hMPV. To test the immunogenicity of the
glycoproteins, the b/h PIV3 vector was engineered to accept
insertions of the genes at two positions. Unique AvrII restric-
tion enzyme sites were introduced into the PIV3 genome up-
stream of the N gene translational start codon (position 1) and
between the bPIV3 N and P genes (position 2). The RSV F or
G genes and the hMPV F gene coupled to the bPIV3 N-P
intergenic region, were inserted as transcriptional cassettes in
positions 1 and 2 of the PIV3 genome to generate bivalent
PIV3/RSV or PIV3/hMPV vaccine candidates (Fig. 1). The
3-most proximal gene positions in the PIV3 viral RNA ge-
nome are transcribed at a higher frequency than genes located
near the 5 end. Therefore, foreign antigens inserted into PIV3
position 1 or 2 should be expressed at high levels eliciting a
strong immune response. The shifting of the PIV3 N gene from
genome position 1 to 2 rendered recombinant virus recovery
less efficient, perhaps due to smaller amounts of N protein
and/or delayed N protein production. A greater number of
transfections were necessary to recover chimeric viruses har-
boring gene insertions in position 1 than gene insertions in
position 2.
Comparison of replication kinetics of chimeric viruses har-
boring RSV or hMPV genes in position 1 or 2 of the PIV3
genome. In order to study whether gene insertions in position
1 or 2 of the PIV3 genome had an effect on virus replication,
multicycle growth curves were carried out for b/h PIV3/RSV
F1, F2, G1, and G2 as well as b/h PIV3/hMPV F1 and F2 in
Vero cells at an MOI of 0.1 (Fig. 2). b/h PIV3/RSV G2 and F2
replicated to peak titers of 8.3 and 7.7 log10 PFU/ml at 72 hpi,
which was only 0.5 to 1.0 log10 lower than the peak titers
observed for the vector b/h PIV3 (Fig. 2A). b/h PIV3 F1 rep-
licated to a peak titer of 6.9 log10, which is 1 log10 lower than
that observed for b/h PIV3 harboring the RSV F gene in
position 2. b/h PIV3/RSV G1 displayed a delayed replication
kinetics compared to b/h PIV3/RSV G2 (Fig. 2A). This delay
in replication observed for b/h PIV3/RSV G1 resulted in peak
titers of 7.0 log10 at 96 hpi (Fig. 2A).
The chimeric virus harboring the hMPV F gene in position
2 of the b/h PIV3 genome replicated as efficiently as the b/h
PIV3 vector. Peak titers observed for b/h PIV3/hMPV F2 at 96
hpi were 8.1 log10 PFU/ml (Fig. 2B). In contrast, the PIV3
expressing hMPV F protein from position 1 displayed a de-
layed onset of virus replication, and the peak titers were de-
creased by 1.8 log10 compared to b/h PIV3/hMPV F2 at 96 hpi.
The highest achievable titer obtained for b/h PIV3/hMPV F1
in Vero cells was 6.3 log10 PFU/ml (Fig. 2B). The virus repli-
cation defect displayed by b/h PIV3/hMPV F1 was more severe
than that of b/h PIV3/RSV G1 or b/h PIV3/RSV F1, suggesting
that the protein inserted could have an effect on virus replica-
tion.
Collectively, the data showed that b/h PIV3 expressing RSV
or hMPV proteins in genome position 1 or 2 replicated to peak
titers of 106 to 108 PFU/ml in Vero cells. Viruses harboring the
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antigen insertion in position 2 replicated more efficiently in
tissue culture than those containing foreign genes in position 1.
Expression of RSV or hMPV proteins by chimeric b/h PIV3.
RSV F or RSV G protein expression by the chimeric b/h
PIV3/RSV was verified by Western blotting. Levels of RSV F
protein expression for b/h PIV3/RSV F1 and b/h PIV3/RSV F2
were compared at 48 hpi at an MOI of 0.1 (Fig. 3A). An
50-kDa band representing the RSV F1 proteolytic fragment
was detected in cells infected with b/h PIV3/RSV F1 and b/h
PIV3/RSV F2 as well as wild-type RSV (Fig. 3A, lanes 1, 2, and
3). The amounts of RSV F1 expressed by b/h PIV3/RSV F1
and b/h PIV3/RSV F2 at 48 hpi were similar. Only low levels of
uncleaved F0 were detected in cells infected with b/h PIV3/
RSV F1 and b/h PIV3/RSV F2, indicating that most of the F0
precursors were efficiently processed during chimeric virus in-
fection as was observed in wild-type RSV infections. As ex-
pected, b/h PIV3 and mock-infected cell lysates did not yield a
signal for RSV F protein (Fig. 3A, lanes 4 and 5). A smaller
band of 26 kDa was also observed in the b/h PIV3/RSV F1
and F2 lysates (Fig. 3A, lanes 1 and 2) that was not present in
wild-type RSV lysates. Since the RSV F MAbs bind to epitopes
in the F1 fragment, it is likely that this proteolytic fragment is
derived from the F1 protein. The absence of this proteolytic
fragment in RSV-infected cells may be due to more authentic
processing of RSV F in the presence of the complete set of
RSV proteins (Fig. 3A, lane 3).
The relative expression of RSV G in b/h PIV3/RSV G1, b/h
PIV3/RSV G2, and wild-type RSV infected cells at a MOI of
0.1 at 48 hpi is shown in Fig. 3B. Both the immature and
glycosylated forms of RSV G that migrated at approximately
50 and 90 kDa, respectively, were detected. b/h PIV3/RSV
G1-infected cells showed levels of RSV G expression similar to
that seen in wild-type RSV-infected cells (Fig. 3B, lanes 1 and
3). However, in b/h PIV3/RSV G2-infected cells, the accumu-
lation of RSV G was reproducibly about two to three times
more than that present in wild-type RSV-infected cells (Fig.
3B, lanes 2 and 3). The higher levels of RSV G expression may
be due to the more 3 proximal position of the RSV G gene in
the PIV3 genome compared to its native position in the RSV
genome. Higher levels of expression were not observed for
RSV G at position 1, which did not replicate as efficiently as
b/h PIV3/RSV G2. RSV G-specific bands were not observed in
cell lysates derived from b/h PIV3- or mock-infected cells (Fig.
3B, lanes 4 and 5).
The recovered b/h PIV3/hMPV viruses were analyzed for
hMPV F protein expression by immunoprecipitation, since the
available hMPV polyclonal antisera did not recognize fully
FIG. 2. (A) Multicycle growth curves of b/h PIV3/RSV F1, F2, G1,
G2, and b/h PIV3 carried out in Vero cells at an MOI of 0.1. (B) Mul-
ticycle growth curves of b/h PIV3/hMPV F1, F2, and b/h PIV3 in Vero
cells at an MOI of 0.1. Cells and supernatants were collected at 0, 24,
48, 72, 96, and 120 hpi. The titers of the samples were determined by
plaque assays on Vero cells.
FIG. 3. RSV or hMPV protein expression by the chimeric b/h PIV3
in Vero cells. (A) Immunoblot of Vero cell lysates infected with b/h
PIV3/RSV F1 or F2 or wild-type RSV A2, b/h PIV3 (at an MOI of
0.1), or mock-infected cells at 48 hpi probed with RSV F-specific
monoclonal antisera. An 50-kDa band corresponding to the pro-
cessed RSV F1 protein was observed for b/h PIV3/RSV F1 and F2
lysates as well as for RSV A2. A larger band of 90 kDa, the un-
cleaved F0 precursor, is also present in relatively smaller quantities in
lanes 1 and 2, indicating that RSV F protein processing occurs effi-
ciently in the chimeric viruses. (B) Western blot of cell lysates infected
with b/h PIV3/RSV G1 or G2, RSV A2, b/h PIV3 (at an MOI of 0.1)
and mock-infected cell lysates at 48 hpi. The Western blot was probed
with RSV G polyclonal antisera and displays mature glycosylated and
immature forms of the RSV G protein expressed by b/h PIV3/RSV G1
or G2 or RSV A2. As expected, a signal was not observed in lysates
derived from Vero cells infected with b/h PIV3 or in mock-infected
cells. (C) b/h PIV3/hMPV F1- or F2-, b/h PIV3-, or mock-infected
35S-labeled cell lysates were harvested 48 hpi and immunoprecipitated
with hMPV-specific polyclonal guinea pig antisera. A band of80 kDa
was observed in cell lysates derived from b/h PIV3/hMPV F1 and F2
that was not present in b/h PIV3- or mock-infected lysates. This size is
consistent with an uncleaved F0 hMPV protein.
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denatured hMPV F protein in a Western blot. The expression
of hMPV F protein by b/h PIV3/hMPV F1 and F2 was shown
by immunoprecipitation with guinea pig hMPV antisera (Fig.
3C). Interestingly, a specific band in the lysates of b/h PIV3/
hMPV F1 and F2 was observed at approximately 80 kDa,
which corresponded to the size of uncleaved F precursor pro-
tein, F0. Although hMPV F protein was expressed by both b/h
PIV3 F1 and F2, it was difficult to compare the amounts pro-
duced by b/h PIV3/hMPV F1 and F2. b/h PIV3/hMPV F1 was
expected to express less hMPV F protein, because it also rep-
licated less efficiently than b/h PIV3/hMPV F2.
Collectively, these data showed that the chimeric b/h PIV3/
RSV expressed the RSV F and G proteins efficiently at both
positions 1 and 2. b/h PIV3/hMPV F expressed the hMPV F
protein from both genome positions. Antigen expression levels
at position 1 or position 2 of the PIV3 genome were similar,
such that either position can be used for gene insertion. How-
ever, position 2 gene insertions appear to be better tolerated by
b/h PIV3, since virus replication was less compromised than for
position 1.
All chimeric b/h PIV3/RSV and b/h PIV3/hMPV viruses
maintained the RSV or hMPV gene inserts stably for multiple
passages. Large-scale production of live viral vaccines requires
multiple passages of the virus in order to achieve high virus
titers. Therefore, it was important to determine whether gene
insertions at position 1 or 2 in chimeric PIV3 were stably
retained following multiple passages in Vero cells. The chi-
meric viruses were serially blind passaged 10 times in Vero
cells. At each passage level, the infected cell lysates were an-
alyzed for RSV or hMPV protein expression by plaque assays
with immunostaining using RSV or hMPV polyclonal antisera.
After passage 10, the introduced RSV or hMPV transcription
units were isolated by RT-PCR. The RSV or hMPV gene
sequences, including gene end and gene start sequences, were
verified by DNA sequence analysis. All b/h PIV3 viruses vec-
toring RSV or hMPV glycoproteins stably maintained the RSV
and hMPV gene cassettes as well as RSV and hMPV protein
expression for 10 passages (data not shown).
The chimeric b/h PIV3/RSV could not be neutralized with
RSV antisera. We studied whether the introduced foreign sur-
face glycoproteins were incorporated into the b/h PIV3 virion
envelope, which may have an effect on virus tropism. In order
to address this, neutralization assays were carried out using b/h
PIV3/RSV (Table 1). RSV F 1200 MAbs neutralized 50% of
wild-type RSV A2 at a 1:2,000 dilution (Table 1). In contrast,
even a dilution of 1:25 did not neutralize any of the chimeric
b/h PIV3/RSV. Similarly, a dilution of 1:400 of the polyclonal
RSV antiserum neutralized 50% of RSV A2, but even at a
dilution of 1:15.6 did not neutralize b/h PIV3 RSV (Table 1).
hPIV3 F C191/9 MAb neutralized 50% of b/h PIV3 as well as
the b/h PIV3/RSV at a dilution of 1:500 (Table 1). The hPIV3
HN 68/2 MAb neutralized b/h PIV3 at a dilution of 1:16,000
and b/h PIV3/RSV at a dilution of 1:32,000 (Table 1). When
these assays were performed under the same conditions, but in
the presence of guinea pig complement, neutralization of b/h
PIV3/RSV was still not observed (data not shown). The results
clearly demonstrated that the RSV proteins were not func-
tional: i.e., the RSV F protein could not functionally substitute
for the hPIV3 F protein that was blocked by the hPIV3 F
antibody. In addition, these results suggested that the RSV
proteins were not present in the virion envelope. There still
remains the possibility of misincorporated RSV F or G pro-
teins in the b/h PIV3 envelope, such that the neutralizing
epitopes were not accessible to RSV antibodies, or the RSV G
or F proteins were present in insufficient amounts to change
the original neutralization properties of the b/h PIV3 virion.
Although the present experiments cannot distinguish between
these possibilities, it is unlikely that b/h PIV3 expressing for-
eign antigens will result in altered virus tropism.
Replication of b/h PIV3/RSV F1, G1, F2, and G2 in Syrian
Golden hamsters. Syrian Golden hamsters represent a permis-
sive small animal model suitable for evaluation of replication
and immunogenicity of genetically engineered b/h PIV3 (9). It
was expected that the introduction of the RSV antigens would
not alter the ability of the chimeric b/h PIV3 to infect and
replicate in hamsters, since the foreign antigens were not func-
tionally incorporated into the virion (Table 1). When animals
were immunized intranasally, the results showed that all of the
chimeric b/h PIV3/RSV replicated to 4.2 to 4.6 log10 TCID50/g
of tissue in the nasal turbinates of hamsters (Table 2). These
levels of replication were similar to those observed for b/h
PIV3, which replicated to 4.8 log10 TCID50/g of tissue (Table
2). Syrian Golden hamsters are only semipermissive for infec-
tion with RSV. The titers of RSV observed in the upper re-
spiratory tract of hamsters were lower by 1.4 log10 TCID50/g
tissue compared to those of b/h PIV3 (Table 2). The b/h PIV3/
RSV harboring the RSV gene in position 1 displayed titers
reduced 0.9 to 1.5 log10 in the lungs of hamsters compared to
b/h PIV3 (Table 2). In contrast, the b/h PIV3/RSV that con-
TABLE 1. Neutralization of b/h PIV3/RSV with RSV and
hPIV3 antisera
Virus used in
neutralization
assay
Reciprocal 50% neutralizing antibody dilution
RSV F
1200 MAb
RSV
PAba
hPIV3 F
C191/9 MAb
hPIV3 HN
68/2 MAb
RSV 2,000 400.0 62.5 	500
b/h PIV3 	25 	15.6 500.0 16,000
b/h RSV F1 	25 	15.6 500.0 32,000
b/h RSV F2 	25 	15.6 500.0 32,000
b/h RSV G1 NDb 	15.6 ND 32,000
b/h RSV G2 ND 	15.6 ND 32,000
a PAb, polyclonal antibody.
b ND, not determined.
TABLE 2. Replication of b/h PIV3 expressing RSV F or G protein
in position 1 or 2 of the PIV3 genome in hamsters
Virusa
Mean virus titer on day 4 postinfection
(log10 TCID50/g of tissue 
 SE)b
Nasal turbinates Lungs
b/h PIV3 4.8 
 0.4 4.4 
 0.3
RSV A2 3.4 
 0.5 3.3 
 0.5
b/h RSV G1 4.2 
 0.7 2.9 
 0.7
b/h RSV F1 4.6 
 0.4 3.5 
 0.2
b/h RSV G2 4.2 
 0.9 4.3 
 0.2
b/h RSV F2 4.6 
 0.6 4.4 
 0.5
a Groups of six hamsters were inoculated intranasally with 106 PFU of the
virus indicated.
b TCID50 assays were read for CPE on day 6 postinfection. SE, standard error.
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tained a gene insertion at position 2 replicated to titers similar
to those observed for b/h PIV3 in the lower respiratory tract of
hamsters (Table 2). Chimeric PIV3 harboring foreign genes in
position 1 or 2 retained the ability to replicate efficiently in the
lower and upper respiratory tracts of hamsters. The introduc-
tion of an additional gene into the b/h PIV3 genome at posi-
tion 1 or 2 did not attenuate the virus significantly in vivo.
b/h PIV3/RSV-vaccinated hamsters were protected from
challenge with RSV A2 or hPIV3 and produced RSV neutral-
izing and PIV3 HAI serum antibodies. In order to evaluate
whether the levels of replication observed for b/h PIV3/RSV
were sufficient to elicit a protective immune response in ham-
sters, the animals were challenged intranasally with 106 PFU of
RSV or hPIV3 per animal on day 28 postvaccination. Animals
immunized with b/h PIV3/RSV were protected completely
from hPIV3 and RSV infection (Table 3). RSV challenge virus
was detected at very low levels, and hPIV3 challenge virus was
not observed in the upper and lower respiratory tract of ham-
sters. Only the animals that had received placebo medium
displayed 4.4 and 4.1 log10 TCID50 of hPIV3 per g of tissue,
and 3.6 and 3.1 log10 PFU of RSV per g of tissue in the upper
and lower respiratory tracts, respectively (Table 3). This study
also showed that animals immunized with RSV were not pro-
tected from challenge with hPIV3. Similarly, animals vacci-
nated with bh/PIV3 displayed high titers of RSV challenge
virus (Table 3).
Prior to administration of the challenge dose, serum samples
were obtained on day 28 from the b/h PIV3/RSV-immunized
animals. The hamster sera were analyzed for the presence of
RSV neutralizing antibodies by using a 50% plaque reduction
assay and for PIV3 HAI serum antibodies by carrying out HAI
assays (Table 4). The results showed that the viruses expressing
the RSV F protein at genome position 1 or 2 displayed RSV
neutralizing antibody titers of 5.5 and 6.9 log2, respectively.
These titers were slightly lower than the antibody titers ob-
served for serum obtained from animals vaccinated with wild-
type RSV (Table 4). In contrast, the viruses expressing the
RSV G protein showed RSV neutralizing antibody titers that
were reduced by 4 log2 compared to wild-type RSV (Table 4).
All of the chimeric b/h PIV3/RSV hamster sera showed levels
of HAI serum antibodies that were reduced by 0.5 to 2.0 log2
compared to the levels observed for b/h PIV3 (Table 4). The
results showed that the chimeric b/h PIV3/RSV could infect
and replicate efficiently in hamsters. A range of neutralizing
serum antibody titers against RSV and hPIV3 were observed
following immunization with the various b/h PIV3/RSV chi-
meric viruses. However, all of the animals immunized were
protected against both RSV and hPIV3 infection upon chal-
lenge with these viruses.
Syrian Golden hamsters were permissive for infection with
chimeric PIV3/hMPV. A small animal model for hMPV has
not yet been identified. However, because the chimeric b/h
PIV3 expressed only a single hMPV protein, it was expected
that the chimeric viruses would replicate efficiently in the re-
spiratory tract of hamsters. Syrian Golden hamsters were in-
fected with b/h PIV3/hMPV F1 and F2 intranasally, and the
ability of these viruses to replicate in the respiratory tract was
analyzed (Table 5). The results showed that b/h PIV3/hMPV
F1 and F2 replicated in the nasal turbinates of hamsters to high
levels of 5.3 and 5.7 log10 TCID50/g of tissue, respectively.
These titers were similar to those observed for b/h PIV3 (4.8
log10 TCID50/g of tissue). For comparison, wild-type hMPV
displayed titers of 5.3 log10 TCID50/g of tissue in the upper
respiratory tracts of hamsters (Table 5). b/h PIV3/hMPV F1
and F2 replicated to titers of 5.7 and 4.6 log10 TCID50/g of
tissue in the lungs of hamsters (Table 5). These titers were also
similar to those observed for b/h PIV3 (5.6 log10 TCID50/g of
tissue). Wild-type hMPV displayed reduced titers of 3.6 log10
TCID50/g tissue in the lower respiratory tract of hamsters (Ta-
TABLE 3. Hamsters immunized with b/h PIV3 expressing
RSV F or RSV G proteins are protected from challenge
with RSV A2 or hPIV3
Immunizing
virusa
Mean hPIV3 titer on day 4
postchallenge (log10
TCID50/g of tissue 
 SE)b
Mean RSV A2 titer on day
4 postchallenge (log10 PFU/
g of tissue 
 SE)b
Nasal
turbinates Lungs
Nasal
turbinates Lungs
b/h PIV3 	1.2 
 0.0 	1.0 
 0.1 3.3 
 0.9 2.9 
 0.4
b/h RSV G1 	1.2 
 0.1 	1.1 
 0.1 	1.0 
 0.3 	0.7 
 0.1
b/h RSV F1 	1.0 
 0.0 	1.0 
 0.0 	0.8 
 0.1 	0.5 
 0.0
b/h RSV G2 	1.2 
 0.2 	1.1 
 0.2 	0.8 
 0.1 	0.8 
 0.3
b/h RSV F2 	1.2 
 0.1 	1.0 
 0.1 	1.3 
 0.6 	1.6 
 1.0
RSV A2 4.5 
 0.6 4.8 
 0.6 	0.6 
 0.2 	0.6 
 0.1
Placebo 4.4 
 0.1 4.1 
 0.1 3.6 
 0.8 3.1 
 0.7
a Virus used to immunize groups of six hamsters on day 0.
b On day 28, the hamsters were challenged with 106 PFU of hPIV3 or RSV A2.
SE, standard error.
TABLE 4. Vaccination of hamsters with b/h PIV3/RSV induces
PIV3 serum HAI and RSV neutralizing antibodies
Virusa
Neutralizing antibody
response to RSV
(mean reciprocal
log2 
 SE)b,c
HAI antibody
response to hPIV3
(mean reciprocal
log2 
 SE)c
RSV 7.9 
 1.0 	2.0 
 0.0
b/h RSV F1 5.5 
 0.5 5.5 
 0.5
b/h RSV G1 3.4 
 0.5 6.6 
 0.7
b/h RSV F2 6.9 
 0.7 6.7 
 0.8
b/h RSV G2 3.4 
 0.5 5.2 
 0.4
b/h PIV3 	2.0 
 0.0 7.2 
 0.5
a Virus used to immunize hamsters.
b The neutralizing antibody titers were determined by a 50% plaque reduction
assay.
c The neutralizing antibody titers of hamster pre-serum were 	2.0, and the
HAI antibody titers were 	2.0.
TABLE 5. Replication of b/h PIV3 expressing hMPV F protein at
position 1 or 2 of the PIV3 genome in hamsters
Virusa
Mean virus titer on day 4 postinfection
(log10 TCID50/g of tissue 
 SE)b
Nasal turbinates Lungs
b/h PIV3 4.8 
 0.2 5.6 
 0.6
b/h hMPV F1 5.3 
 0.5 5.7 
 0.4
b/h hMPV F2 5.7 
 0.5 4.6 
 0.3
hMPV 5.3 
 0.1 3.6 
 0.3
a Groups of six hamsters were inoculated intranasally with 106 PFU of the
virus indicated.
b TCID50 assays were read for CPE on day 10 postinfection. SE, standard
error.
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ble 5). These data demonstrated that b/h PIV3/hMPV F1 and
F2 could efficiently infect and replicate in the upper and lower
respiratory tracts of Syrian Golden hamsters and suggested
that hamsters are a suitable small animal model to study im-
munogenicity of hMPV as well as hMPV vaccine candidates.
b/h PIV3/hMPV-vaccinated hamsters were protected from
challenge with hMPV or hPIV3 and produced hMPV neutral-
izing and PIV3 HAI serum antibodies. As predicted, chimeric
b/h PIV3 expressing the hMPV F protein in position 1 or 2
replicated to high levels in the respiratory tracts of hamsters
(Table 5). On day 28 postimmunization, the vaccinated ani-
mals were challenged intranasally with 106 PFU of hPIV3 or
hMPV. Viruses present in the nasal turbinate and lung tissues
4 days postchallenge were quantified by plaque assays. Animals
that had received b/h PIV3/hMPV F1 or F2 were completely
protected from the hMPV challenge in the lower respiratory
tract. As expected, wild-type hMPV-immunized animals were
protected from hMPV challenge. Only animals that had re-
ceived placebo medium displayed high hMPV challenge virus
titers of 4.5 log10 PFU/g of lung tissue (Table 6). In the upper
respiratory tract, b/h PIV3/hMPV F1 protected only partially
from hMPV challenge. A decrease of 2.5 log10 was observed in
b/h PIV3/hMPV F1-vaccinated animals compared to the
hMPV challenge virus titers present in the placebo-treated
control, which were 6.0 log10 PFU/g of nasal turbinate tissue.
In contrast, b/h PIV3/hMPV F2 protected the hamsters com-
pletely in the upper respiratory tract, and only trace amounts
of hMPV challenge virus were detected (Table 6). All b/h
PIV3/hMPV F-immunized animals were completely protected
from challenge with hPIV3. Only the animals that had received
placebo medium for immunization displayed high levels of
hPIV3 in the lung and nasal turbinate tissues, resulting in titers
of 4.5 and 4.3 log10 TCID50/g tissue, respectively (Table 6).
Serum samples were obtained from the hamsters on day 28
prior to administration of the challenge virus and analyzed for
the presence of hMPV neutralizing antibodies and HAI serum
antibodies (Table 7). High levels of hMPV neutralizing anti-
bodies, 7.4 log2, were observed for sera derived from wild-type
hMPV-infected animals. Sera obtained from b/h PIV3/hMPV
F1- or F2-vaccinated hamsters showed neutralizing antibody
titers of 7.8 and 7.4 log2, respectively, which were equivalent to
those observed for wild-type hMPV sera (Table 7). The HAI
antibody levels were also similar to those observed for b/h
PIV3, the virus vector. The chimeric b/h PIV3/hMPV F1 and
F2 displayed HAI titers of 5.8 and 6.3 log2, respectively, which
are 1.2 and 0.7 log2 lower than the HAI titers obtained from
b/h PIV3-infected hamster sera (Table 7).
In summary, the results showed that b/h PIV3 expressing
hMPV F protein in position 1 or 2 of the b/h PIV3 genome can
efficiently infect and replicate in Syrian Golden hamsters and
induce protective immunity against challenge with hPIV3 and
hMPV. The immunization of hamsters with these chimeric
viruses also elicited the production of hMPV neutralizing an-
tibodies and HAI serum antibodies with levels similar to those
observed for wild-type hMPV or b/h PIV3, respectively.
DISCUSSION
The effect of foreign gene insertion in position 1 or 2 of the
b/h PIV3 genome on in vitro and in vivo virus replication and
foreign antigen expression was evaluated in this study. The
three antigens chosen were the RSV F, RSV G, and hMPV F
surface glycoproteins, all of which have the potential to be
incorporated into the b/h PIV3 virion. We wanted to study
whether all foreign membrane glycoproteins expressed by b/h
PIV3 would produce viruses with similar phenotypes or
whether the type of protein inserted would yield viruses with
different replication characteristics. PIV3 genome positions 1
and 2 were expected to yield the highest levels of foreign
protein expression since paramyxoviruses transcribe the 3-
most proximal genes with the highest frequency. Foreign gene
insertions in position 1 could interfere with virus replication by
delaying and/or reducing bPIV3 N protein expression, which
now takes place from genome position 2. Insertion in the first
position also has a greater potential for effecting initiation of
transcription and replication of the antigenome. In contrast,
gene insertions in position 2 should alter the N-P mRNA ratio,
which may impair virus replication as well. Therefore, it was of
interest to test which of the genome positions would better
tolerate foreign gene insertions without compromising virus
replication.
Our studies showed that b/h PIV3 expressed the RSV F, RSV
G, or hMPV F proteins efficiently from genome positions 1 and 2.
Curiously, the 3 proximal location of the foreign antigens did not
result in enhanced protein expression compared to that of wild-
type RSV, as expected from the transcription gradient known to
be generated by nonsegmented negative-strand RNA viruses.
Chimeric b/h PIV3/RSV G expressed slightly less RSV G protein
TABLE 6. Hamsters immunized with b/h PIV3 expressing hMPV F
protein are protected from challenge with hMPV or hPIV3
Challenge virus
Mean hPIV3 titer on day 4
postchallenge (log10
TCID50/g of tissue 
 SE)b
Mean hMPV titer on day 4
postchallenge (log10
PFU/g of tissue 
 SE)b
Immunizing
virusa
Nasal
turbinates Lungs
Nasal
turbinates Lungs
b/h PIV3 	1.3 
 0.2 	1.1 
 0.1 NDc ND
b/h hMPV F1 	1.3 
 0.1 	1.1 
 0.1 3.5 
 0.8 	0.5 
 0.2
b/h hMPV F2 	1.2 
 0.1 	1.2 
 0.1 	0.9 
 0.4 	0.5 
 0.1
hMPV ND ND 	0.8 
 0.3 	0.4 
 0.0
Placebo 4.3 
 0.3 4.5 
 0.5 6.0 
 0.3 4.5 
 1.3
a Virus used to immunize groups of six hamsters on day 0.
b On day 28, the hamsters were challenged with 106 PFU of hPIV3 or hMPV/
NL/1/00.
c ND, not determined.
TABLE 7. Vaccination of hamsters with b/h PIV3/hMPV induces
PIV3 serum HAI and hMPV neutralizing antibodies
Virusa
Neutralizing antibody
response to hMPV (mean
reciprocal log2 
 SE)b,c
HAI antibody
response to hPIV3 (mean
reciprocal log2 
 SE)c
hMPV 7.4 
 1.5 	2.0 
 0.0
b/h hMPV F1 7.8 
 1.0 5.8 
 0.7
b/h hMPV F2 7.4 
 1.0 6.3 
 0.5
b/h PIV3 	2.0 
 0.0 7.0 
 0.8
a Virus used to immunize hamsters.
b The neutralizing antibody titers were determined by a 50% plaque reduction
assay. SE, standard error.
c The neutralizing antibody titers of hamster pre-serum were 	2.0, and the
HAI antibody titers were 	2.0.
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from position 1 than from position 2; however, this effect was not
observed for b/h PIV3/RSV F1 or b/h PIV3/hMPV F1. The RSV
F0 protein expressed by PIV3 was processed into F1 and F2, like
the RSV F protein derived from wild-type RSV. A smaller pro-
teolytic fragment accumulated to large amounts in lysates derived
from b/h PIV3/RSV F1 and F2, which was not observed in wild-
type RSV lysates. The precise origin of this peptide is not known
for certain, but the antibodies used to probe the Western blot
recognized epitopes in the N-terminal half of the glycoprotein.
While the precursor RSV F0 and the processed RSV F1 were
observed for b/h PIV3/RSV F1 and F2, F protein processing was
not observed for hMPV F expressed by b/h PIV3 from position 1
or 2. b/h PIV3/hMPV F1 or F2 displayed only protein bands
corresponding in size to the uncleaved F0 protein precursor.
Analysis of the F protein cleavage site revealed that the hMPV F
protein cleavage site consisted of multiple charged amino acid
residues (RQSR) but differed from the conserved furin protease
cleavage site seen in related viruses like RSV or APV (RKRR
and RRRR, respectively). Underlining indicates altered amino
acids that are different in hMPV. Sendai virus, a paramyxovirus
with a nonconsensus furin protease cleavage site needs exogenous
protease for multiple rounds of replication in tissue culture (19).
The “weak” cleavage site of the hMPV F protein may therefore
be responsible for the presence of only the F0 protein detected by
immunoprecipitation in this study, since the F1 and F2 fragments
would be present only at low levels. Inefficient F protein cleavage
may hinder the cell-to-cell spread of hMPV, accounting for slow
replication in tissue culture, and may explain the trypsin require-
ment of some hMPV strains (25).
PIV3 harboring foreign genes in position 1 was more difficult
to recover by reverse genetics than viruses harboring gene
insertions in position 2. This may be due to an impairment of
bPIV3 N protein levels, since the N gene was moved to genome
position 2 in b/h PIV3 harboring foreign genes in position 1.
An analysis of the kinetics of virus replication showed that
viruses harboring foreign gene insertions in position 2 repli-
cated to peak titers observed for b/h PIV3, the virus vector. In
contrast, viruses containing the gene insertion in position 1 of
the PIV3 genome displayed a delayed onset of peak virus
replication and reduced virus peak titers compared to b/h
PIV3. This was most pronounced for b/h PIV3/hMPV F1 and
b/h PIV3/RSV G1, which suggested that the type of foreign
gene inserted into the PIV3 genome also has an effect on virus
replication, even though all of the antigens are surface glyco-
proteins with similar functions. All chimeric PIV3 viruses with
gene insertions in position 2 replicated to high titers of 107 to
108 PFU/ml in Vero cells, and thus position 2 is a better
position for maximum level of foreign gene expression.
To study whether foreign gene insertions had an effect on in
vivo virus replication, hamsters were infected intranasally with
the chimeric b/h PIV3 expressing RSV or hMPV proteins.
Only b/h PIV3 expressing the RSV F or RSV G protein in
position 1 displayed restricted replication in the lower respira-
tory tract of hamsters. However, protection from challenge
with hPIV3 or RSV was not affected by the lower levels of
replication in the lungs of hamsters observed for b/h PIV3/
RSV G1 or F1. Notably, b/h PIV3/RSV F1 displayed lower
titers of RSV neutralizing and HAI serum antibodies than b/h
PIV3/RSV F2. High levels of replication were observed for b/h
PIV3/hMPV F1 and F2, but b/h PIV3/hMPV F1 protected
immunized hamsters only partially in the upper respiratory
tract. Additional studies are necessary to determine the reason
for partial protection displayed by b/h PIV3/hMPV F1. The
levels of RSV neutralizing and PIV3 HAI antibody titers of b/h
PIV3/hMPV F1 and F2 were not affected by genome position,
because both viruses elicited antibody titers equivalent to those
observed for wild-type hMPV.
b/h PIV3 had been used previously to express RSV proteins
and to demonstrate immune protection in hamsters and pri-
mates (20, 21). In these studies, the genes encoding the RSV F
or G protein were inserted singly in the 3 proximal position of
the PIV3 genome or inserted in tandem as a combination of
RSV G and F. Characterization of RSV protein expression did
not reveal a good correlation between genome position and the
amount of RSV protein expressed. The data showed that RSV
F protein was expressed at smaller amounts from position 1 in
the PIV3 genome (b/h PIV3-FA) than from the RSV F gene
located in position 2 in b/h PIV3 GAFA, which is not expected
in the presence of a transcriptional gradient. Similarly, RSV G
protein expression for the single RSV G gene inserted at the 3
proximal position was higher than that observed for b/h PIV3
RSV GAFA, in which the RSV G gene is also located at the
3-most proximal end of the viral genome (21). These results
suggested that PIV3 genome location alone may not be the
sole determinant for levels of foreign gene expression. The
gene start or gene end sequences and/or RNA elements that
direct mRNA stability or translation efficiency may also play a
role in determining efficiency of viral mRNA transcription and
viral protein expression. Interestingly, the RSV neutralizing
antibody titers present in sera derived from hamsters infected
with b/h PIV3/RSV F1 or G1 in the study by Schmidt et al. (20)
were higher than those in our data, although the neutralization
antibody titers for wild-type RSV sera from both studies were
identical. This difference in antibody titers may be due to
higher replication levels of b/h PIV3/RSV F1 or G1 generated
by Schmidt et al. in the respiratory tract of hamsters. b/h
PIV3/RSV F1 and G1 displayed titers 0.5 and 1.7 log10 higher,
respectively, in the upper respiratory tract and 1.1 and 2.2 log10
higher, respectively, in the lower respiratory tract of hamsters
than the replication titers observed in this study (20). The
increased levels of viral replication in the respiratory tract of
hamsters may result in higher RSV neutralizing antibody titers.
The origins of the hPIV3 F and HN genes, the Texas strain for
the b/h PIV3 generated in this study and the JS strain for the
b/h PIV3 generated by Schmidt et al. (20), may direct the in
vivo hamster replication efficiencies observed for the chimeric
viruses. The neutralizing antibody titers of b/h PIV3/RSV F1
and G1 hamster sera were also higher than wild-type RSV
serum titers (20). In contrast, the neutralizing antibody titers of
wild-type RSV-infected rhesus monkeys were higher than
those observed for b/h PIV3/RSV F1 or G1 primate sera when
the same viruses were evaluated in rhesus monkeys, albeit
wild-type RSV replicated to lower titers in rhesus monkeys
than chimeric PIV3/RSV (21). In order to resolve these dis-
crepancies, it would be necessary to compare the b/h PIV3/
RSV F1 and G1 viruses generated in the two different labora-
tories directly in the same study to determine whether the
origin of the hPIV3 surface glycoprotein genes and/or other
genetic components, such as the types of gene start and stop
sequences, can influence virus replication and immunogenicity.
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In this study, the chimeric b/h PIV3 viruses expressing the
RSV or hMPV surface glycoproteins were shown to function as
bivalent vaccines in a small animal model. These viruses have
characteristics that make them suitable for evaluation as live
attenuated virus vaccines for RSV, hMPV, and hPIV3. The
chimeric viruses grow to high titers in tissue culture. The in-
serted antigens of the chimeric b/h PIV3 were genetically sta-
ble and maintained up to passage 10 in Vero cells. In vacci-
nated hamsters, the viruses elicited a protective immune
response upon challenge with wild-type hPIV3, RSV, and
hMPV. The challenges were carried out with homotypic vi-
ruses; however, the degree of amino acid identity is very high
for the two subgroups of RSV A and B (89%), as well as the
two subgroups of hMPV A and B (95%), and therefore immu-
nological cross protection is expected to occur. Although this
remains to be tested directly, RSV F MAbs such as Synagis can
neutralize RSV originating from subgroup A as well as sub-
group B. The chimeric viruses induced an effective neutralizing
antibody response to the vectored non-PIV3 glycoproteins de-
spite not being incorporated into the virion. The latter finding
should allay concerns that a change in viral tropism is not likely
as a consequence of new virus-cell receptor interactions of the
b/h PIV3 expressing glycoproteins from RSV or hMPV. The
b/h PIV3/RSV F2 and b/h PIV3/hMPV F2 viruses will be
further evaluated for safety and efficacy in a primate model.
This study demonstrated the utility and versatility of
b/hPIV3 as a virus vector for expression and delivery of three
different foreign viral antigens: RSV F, RSV G, and hMPV F.
The ease, speed, and effectiveness of generating potential vac-
cine candidates for newly discovered viral pathogens for which
infectious cDNAs and recombinant virus recovery systems are
not available further underscore the importance of developing
b/h PIV3 as a virus vaccine vector.
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